Professor Hendrik-Tobias Arkenau

Professor and consultant of medical oncology at University College London and the Medical Director of Sarah Cannon Research Institute, London, UK.

Country

United Kingdom

Speciality

Oncology

Subspeciality

Cancer Immunotherapy and Gastrointestinal and liver Cancers

Experience

2000 years

Languages

English, German

Areas of expertise

Gastro-intestinal cancer
Stomach cancer
Liver and biliary cancer
Pancreatic cancer
Bowel cancer
Cancer Immunotherapy
Skin cancer
Melanoma
Bile Duct Cancer
Oesophagus Cancer
Biological Therapy
Gallbladder Cancer

About the expert

Professor Arkenau is the Medical Director of the Sarah Cannon Research Institute, London, UK. Professor Arkenau is a Fellow of the Royal College of Physicians, and a member of The German Cancer Society, the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Society for Medical Oncology. He has published numerous peer-reviewed articles and book chapters and regularly contributes at international and national meetings.He has published

Prof. Hendrik-Tobias Arkenau graduated from Hanover Medical School, Germany in 2000. He then completed his specialist training in oncology with a special interest in gastrointestinal cancer and melanoma, across numerous centers of excellence, including the Royal Marsden Hospital, London, UK and that was from 2005 until 2008. Prof. Hendrik Tobias Arkenau specialises in the treatment of gastrointestinal cancer, stomach cancer, liver cancer, pancreatic cancer, bowel cancer, and immunotherapies.

Prof. Arkenau is appointed as a Professorial Research Associate on University College London faculty and he holds an Honorary Consultant post with UCL Hospitals. He is the founding Medical Director of the Sarah Cannon Research Institute, London, UK since 2010 and he is currently the Executive Medical Director for the institute.

Prof. Arkenau is a Fellow of the Royal College of Physicians, and a member of The German Cancer Society, American Society of Clinical Oncology , American Association for Cancer Research and European Society for Medical Oncology.

Throughout his career, he has published numerous peer-reviewed articles and book chapters and regularly contributes at international and national meetings.

Since its inauguration in 2010, Prof. Arkenau has built up a trial portfolio of >80 early clinical trials. As Chief- and Principal Investigator he is actively involved in protocol development, toxicity review, pharmacokinetic analysis, biomarker, and strategic development of new anti-cancer drugs, including immunotherapies.

Executive Medical Director
2010 - Today
Sarah Cannon Research Institute London, United Kingdom
Clinical Lead Oncology Service Line
2015 - Today
HCA International Ltd, London, United Kingdom
Professor
2011 - Today
University College London
Team Leader Clinical Drug Development
2008 - 2010
University of New South Wales, Australia
Senior Clinical Research Fellow, Oncology Drug Development
2005 - 2008
Royal Marsden Hospital, London, United Kingdom
Assistant Doctor
2000 - 2005
Hospital Bremen East, Bremen, Germany

MD, PhD Medicine

Medical School Hanover, Hanover, Germany

2000
MD Medicine

Martin Luther University Halle, Halle, German

1996

Fellow of the Royal College of Physicians
German Cancer Society
American Association for Cancer Research
European Society for Medical Oncology

Other experts inthe same specialty

Doctor Premini Mahendra

Consultant Haemato-Oncologist, Birmingham, United Kingdom